1422386-21-7

Basic information

• Product Name: 1-(3-chloro-2-fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester
• Synonyms: 1-(3-chloro-2-fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester
• CAS NO: 1422386-21-7
• Molecular Weight: 282.702
• Mol File: 1422386-21-7.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 1-(3-chloro-2-fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-chloro-2-fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester(1422386-21-7)
• EPA Substance Registry System: 1-(3-chloro-2-fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester(1422386-21-7)

Safety Data

• Hazardous Substances Data: 1422386-21-7(Hazardous Substances Data)

Upstream product

• 141-97-9 ethyl acetoacetate 
• 396075-11-9 2-fluoro-3-chlorophenylhydrazine 
• 134653-70-6 ethyl 2-[(dimethylamino)methylene]-3-oxobutanoate 
• 517920-75-1 (3-chloro-2-fluorophenyl)hydrazine hydrochloride 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 203186-58-7 (E)-ethyl 2-((dimethylamino)methylene)-3-oxobutanoate 

Downstream Products

• 1422386-19-3 1-(3-chloro-2-fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 

Relevant articles and documents

Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups

Factor XIa (FXIa) inhibitors are promising novel anticoagulants, which show excellent efficacy in preclinical thrombosis models with minimal effects on hemostasis. The discovery of potent and selective FXIa inhibitors which are also orally bioavailable has been a challenge. Here, we describe optimization of the imidazole-based macrocyclic series and our initial progress toward meeting this challenge. A two-pronged strategy, which focused on replacement of the imidazole scaffold and the design of new P1 groups, led to the discovery of potent, orally bioavailable pyridine-based macrocyclic FXIa inhibitors. Moreover, pyridine-based macrocycle 19, possessing the phenylimidazole carboxamide P1, exhibited excellent selectivity against relevant blood coagulation enzymes and displayed antithrombotic efficacy in a rabbit thrombosis model.

BIARYL PYRAZOLES AS NRF2 REGULATORS

The present invention relates to biaryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

FACTOR XIA NEW MACROCYCLE BEARING A NON-AROMATIC P2' GROUP

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.